May 2016

A well-tailored financial counseling program can help a practice minimize exposure to financial risks due to increasing patient responsibility.

The Evidence Blocks developed by the National Comprehensive Cancer Center make up one of the most ambitious attempts so far to incorporate data from multiple platforms to create a resource with broad applicability for the healthcare community.

Oncology practices may soon find themselves working directly with employers on benefits and treatment strategies.

Comprehensive Cancer Centers of Nevada's exponential expansion is, in part, a result of both the surging local headcount and the national trend toward oncology practice consolidation.

Members of Congress on both sides of the aisle have responded to urgings from the oncology sector that they join in the effort to quash a proposal to change the rule on physician pay under Medicare Part B.

For most oncologists at Texas Oncology, healthcare quality reporting to the CMS went smoothly, but serious complications were encountered.

A not-so-subtle change in the physician drug payment scheme from The Centers for Medicare & Medicaid Services could be the proverbial straw that broke the camel’s back.

Are the medicines of tomorrow, which are expected to cost in the hundreds of thousands of dollars, only going to be available to the privileged few or can we find solutions so they can be available to most of the population?

Enzalutamide (Xtandi) pricing heightens the likelihood of pre-authorization requirements and cost-sharing arrangements that may be financially burdensome, ruinous, or simply impossible to meet.

Social media has become an outlet for expressing frustration with the struggle to get insurance approvals for oncology tests and treatments.